glp 1 agonists oral Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Five Unexpected New Uses for

As more GLP-1 prescriptions are written to manage not just diabetes and cardiovascular disease but also obesity, a key question emerges: What is the role of patient engagement and chronic disease management when prescribing these drugs

June 2025: The European Medicines Agencys (EMAs) safety committee concluded that NAION is a very rare potential side effect of semaglutide medicines, like Wegovy

Weight Loss Outcomes Clinical trials consistently show Tirzepatide produces greater fat loss than Semaglutide

Oral Non Peptide GLP 1 Receptor Agonist Market is segmented into Type, Application, Distribution Channel, and By Region Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Roche Holding AG, Structure Therapeutics Inc., Amgen Inc., Viking Therapeutics Inc., AstraZeneca PLC, Boehringer Ingelheim, Merck & Co., Inc., Carmot Therapeutics, Sciwind Biosciences, Hanmi Pharmaceutical, Metsera Inc., Regor Therapeutics Group, Chugai Pharmaceutical Co., Ltd., Zealand Pharma A/S, Altimmune Inc., Innovent Biologics Inc., and Jiangsu Hengrui Pharmaceuticals